Pieris Pharmaceuticals

Home » Pieris Pharmaceuticals

Secondary

Pieris Pharmaceuticals

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way.

Symbol

PIRS

Last Closing Price
$9.45

Shares
5,500,000

Effective Date
February 14, 2018

Underwriters
Jefferies, Cowen, Evercore ISI

To view the prospectus for Pieris Pharmaceuticals, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253